Healthcare provider profile · identity verified

Robert E. Terbrack, D.O.

Family Practice · STOUGHTON, WI · NPI 1023334448

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	301	87
Lisinopril	Lisinopril	222	61
Levothyroxine Sodium	Levothyroxine Sodium	194	45
Omeprazole	Omeprazole	175	42
Amlodipine Besylate	Amlodipine Besylate	163	55
Losartan Potassium	Losartan Potassium	140	46
Duloxetine Hcl	Duloxetine Hcl	113	17
Metoprolol Succinate	Metoprolol Succinate	112	31
Metformin Hcl Er	Metformin Hcl	108	36
Gabapentin	Gabapentin	106	32
Metformin Hcl	Metformin Hcl	93	26
Eliquis	Apixaban	92	20
Oxycodone Hcl	Oxycodone Hcl	89	18
Simvastatin	Simvastatin	82	28
Trazodone Hcl	Trazodone Hcl	77	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	75	13
Pantoprazole Sodium	Pantoprazole Sodium	75	22
Fluoxetine Hcl	Fluoxetine Hcl	73	19
Hydrochlorothiazide	Hydrochlorothiazide	70	27
Ozempic	Semaglutide	69	11
Furosemide	Furosemide	63	19
Albuterol Sulfate Hfa	Albuterol Sulfate	62	30
Baclofen	Baclofen	59	13
Tamsulosin Hcl	Tamsulosin Hcl	57	19
Amitriptyline Hcl	Amitriptyline Hcl	53	suppressed
Citalopram Hbr	Citalopram Hydrobromide	53	11
Trulicity	Dulaglutide	52	suppressed
Glipizide Er	Glipizide	50	15
Warfarin Sodium	Warfarin Sodium	49	12
Sertraline Hcl	Sertraline Hcl	48	19
Lorazepam	Lorazepam	46	11
Rosuvastatin Calcium	Rosuvastatin Calcium	46	12
Tizanidine Hcl	Tizanidine Hcl	45	14
Naproxen	Naproxen	44	suppressed
Allopurinol	Allopurinol	43	12
Fluticasone Propionate	Fluticasone Propionate	43	22
Meloxicam	Meloxicam	43	13
Carvedilol	Carvedilol	41	19
Tramadol Hcl	Tramadol Hcl	40	suppressed
Bupropion Xl	Bupropion Hcl	38	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	35	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Atenolol	Atenolol	32	suppressed
Diclofenac Sodium	Diclofenac Sodium	32	12
Escitalopram Oxalate	Escitalopram Oxalate	31	suppressed
Lovastatin	Lovastatin	31	suppressed
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Pregabalin	Pregabalin	29	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	28	suppressed
Famotidine	Famotidine	28	suppressed
Novolog Flexpen	Insulin Aspart	28	suppressed
Celecoxib	Celecoxib	27	suppressed
Glimepiride	Glimepiride	27	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	27	11
Propranolol Hcl Er	Propranolol Hcl	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	12
Doxycycline Hyclate	Doxycycline Hyclate	25	15
Propranolol Hcl	Propranolol Hcl	25	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	24	suppressed
Clonazepam	Clonazepam	24	11
Ondansetron Hcl	Ondansetron Hcl	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Ondansetron Odt	Ondansetron	22	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Jardiance	Empagliflozin	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Buprenorphine	Buprenorphine	20	suppressed
Tresiba Flextouch U-100	Insulin Degludec	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Montelukast Sodium	Montelukast Sodium	19	suppressed
Prednisone	Prednisone	19	18
Linzess	Linaclotide	18	suppressed
Methadone Hcl	Methadone Hcl	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Valsartan	Valsartan	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Diazepam	Diazepam	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Liothyronine Sodium	Liothyronine Sodium	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Progesterone	Progesterone, Micronized	14	suppressed
Brilinta	Ticagrelor	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Estradiol (Once Weekly)	Estradiol	13	suppressed
Risperidone	Risperidone	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Fentanyl	Fentanyl	12	suppressed
Finasteride	Finasteride	12	suppressed
Gemtesa	Vibegron	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Glipizide	Glipizide	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Oxycontin	Oxycodone Hcl	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error